Ora, Inc.

Release Summary

Conjunctival Allergen Challenge model recently confirmed Phase 2 clinical results of Sustained Release Dexamethasone, a drug-eluting intracanalicular depot, under development by Ocular Therapeutix

Ora, Inc.